By suppressing the expression of anterior pharynx-defective-1α and -1β and inhibiting the aggregation of β-amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice.
Level 5 - mechanism / opinion, no new human data
Animal model and in vitro mechanistic study
PubMed 26293690 · doi:10.1096/fj.15-275578
What was done
Researchers evaluated the effects of magnesium-L-threonate (MgT) in APPswe/PS1dE9 transgenic Alzheimer's disease model mice and neuronal cultures. They investigated cognitive decline, amyloid-β (Aβ) clearance, activation of ERK1/2 and PPARγ signaling pathways, and the expression of anterior pharynx-defective (APH)-1α and APH-1β in response to MgT and CSF Aβ oligomers.
What was found
MgT treatment activated neuronal ERK1/2 and PPARγ pathways, which suppressed APH-1α and APH-1β expression by >80%. Exposure to CSF Aβ oligomers increased APH-1α/1β expression by >2.5-fold. MgT treatment enhanced Aβ clearance and inhibited cognitive decline in the transgenic mice, though specific cognitive test metrics, exact animal counts, and p-values were not provided in the abstract.
Why it matters
The study outlines a specific molecular mechanism—suppression of γ-secretase components APH-1α/1β through ERK1/2 and PPARγ signaling—by which brain magnesium reduces amyloid-β deposition in an Alzheimer's disease mouse model.
Limits
Findings are limited to transgenic mice and cell culture models, which may not directly translate to human clinical Alzheimer's disease. The abstract omits sample size, MgT dosage, treatment duration, and quantitative behavioral data.
Cited by
- supports In mouse models, magnesium threonate at a human equivalent dose of 8.1 mg/kg body weight improves cognition and reduces amyloid-beta plaques.